Takeda Pharmaceutical Company and Innovent Biologics have orchestrated a global strategic alliance worth as much as $11.4 billion to expedite the creation of cutting-edge oncology drugs for solid tumors.
.png "AstraZeneca's Imfinzi Shows Major Gains in Gastric Cancer")
AstraZeneca's Imfinzi (durvalumab) has demonstrated a significant increase in survival for early-stage gastric (GC) and gastroesophageal junction cancers (GEJC), according to new data from the European Society for Medical Oncology (ESMO) 2025...
.png "Merck's Pimicotinib Shows Durable Gains in TGCT Phase 3 Study")
Merck KGaA, a premier science and technology company, today revealed up to-date Phase 3 data from the global MANEUVER trial of pimicotinib, an investigational CSF-1R antagonist developed in collaboration with Abbisko Therapeutics for the treatment...
Torrent Pharmaceuticals, one of the top Indian pharmaceutical companies, is going to make a significant financial move after getting the green light from the regulatory body for its acquisition of JB Chemicals & Pharmaceuticals.
Biocon Biologics Ltd (BBL) has reached significant achievement with Health Canada's approval of Yesintek (ustekinumab injection) and Yesintek IV, which are biosimilars of Stelara and Stelara IV. The Notice of Compliance was issued on...
Eli Lilly and Cipla have signed a strategic cooperative agreement to distribute and promote tirzepatide in India. Cipla will create a new brand, Yurpeak, to expand access to the drug in areas beyond cities where Lilly is already present.
Austria's Modern Mayr Medicine, a world leader in gut health and natural preventive medicine, has announced a historic strategic relationship with Biopeak, India's first full-stack precision health and wellness platform
Aurobindo Pharma experienced an increase of 1.14%, reaching Rs 1,113.55, following the establishment of a new wholly owned subsidiary in Chile, named Eugia Pharma Chile SpA, by its wholly owned step-down subsidiary, Eugia Pharma B.V.
Johnson & Johnson announced impressive outcomes for a subcutaneous formulation of amivantamab (Rybrevant) which achieved a 45% overall response rate (ORR) in individuals with advanced head and neck squamous cell carcinoma (HNSCC)...
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of its Ropivacaine Hydrochloride Injection USP in three single-dose vial strengths
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")